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ABSTRACT 
Gene therapy of severe combined immunodeficiencies has been proven to be effective to provide 
sustained correction of the T cell immunodeficiencies. This has been achieved for 2 forms of 
SCID, i.e SCID-X1 (c deficiency) and adenosine deaminase deficiency. Occurrence of gene 
toxicity generated by integration of first generation retroviral vectors, as observed in the SCID-
X1 trials has led to replace these vectors by self inactivated (SIN) retro(or lenti) viruses that may 
provide equivalent efficacy with a better safety profile. Results of ongoing clinical studies in 
SCID as well as in other primary immunodeficiencies, such as the Wiskott Aldrich syndrome, 
will be thus very informative.  
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1.  Introduction 
The rationale for gene therapy in primary T cell immunodeficiencies 
There are many reasons why gene therapy has been developed in the field of primary 
immunodeficiencies (PIDs) over the last 20 years. Many PIDs are life-threatening conditions - 
notably severe combined immunodeficiencies (SCIDs) affecting T cell development and 
function, Wiskott Aldrich syndrome (WAS), hemophagocytic lymphohistiocytosis (HLH), innate 
immune deficiencies (such as chronic granulomatous disease or Mendelian susceptibility to 
mycobacterial disease) and inherited autoimmune syndromes. The remarkable progress in 
treating PIDs has mostly been based on allogeneic hematopoietic stem cell transplantation 
(HSCT).(Gennery et al., 2010) However, this approach is far from perfect and serious adverse 
events (SAEs) can still occur (such as graft-versus-host disease (GVHD)). In particular, GVHD 
can damage the thymus and compromise the reconstitution of T cell immunity. The limitations of 
HSCT are necessarily more pronounced in patients who lack HLA-compatible donors. 
Conversely, the success of HSCT provides a rational basis for the autotransplantation of 
transduced stem cells - the current approach in gene therapy for PIDs. Most PIDs display 
Mendelian inheritance, so that introduction of a normal copy of the mutated gene into the 
patient's cells should (in principle) be effective. The fact that disease-related genes have now 
been found for most PIDs (Notarangelo et al., 2009) makes gene therapy a feasible approach for 
many of these conditions. 
For some PIDs (e.g. T cell immunodeficiencies), it has become clear that transduced precursor 
cells can have a selective growth advantage. In several T cell PIDs, the occurrence of somatic 
mutations positively modifies the mutated genes and leads to the development of functional T 
cells; the observed attenuation of disease phenotypes strongly supports this concept. This growth 
advantage is based on (i) the tremendous ability of T cell precursors in the thymus to divide in an 
4 
 
interleukin-7-dependent manner and, following expression of the pre-T cell receptor (pre-TCR), 
(ii) positive selection and (iii) the very long life span of mature T cells. One can thus expect a few 
transduced T cell precursors to give rise to a full, stable T cell pool in a given individual. Hence, 
SCID is considered to be an optimal model for assessing the feasibility of gene therapy. 
 
 Gene transfer technology 
In the meantime, significant advances in viral vector technology have enabled the transduction of 
dividing cells and thus replication of the transgene in progeny cells. Replication-defective 
retroviral vectors have been based on murine oncoretroviruses (the  retrovirus), simian and 
human lentiviral viruses, spuma viruses and transposons (Verma and Weitzman, 2005). A key 
advance was the creation of “self-inactivating" (SIN) viruses in which the absence of enhancer 
elements in their long terminal repeats (LTRs) makes them less able to transactivate endogenous 
genes after genome integration (see below) (Yu et al., 1986). In the absence of enhancers, several 
internal promoters can be used to drive transgene transcription. Culture conditions for the 
transduction of hematopoietic progenitor cells have been improved by selecting the best cytokine 
cocktails and promoting virus/cell interaction by the addition of fibronectin fragments. 
 
 Gene therapy in SCIDs 
Following the advent of this vector technology, clinical trials were successfully initiated for 
SCID-X1 (c deficiency) in 1999 and then adenosine deaminase (ADA) deficiency. To date, gene 
therapy results are available for 20 patients with typical X-linked SCIDs, five patients with 
atypical SCIDs (n=5) and 38 patients with ADA deficiency (Cavazzana-Calvo et al., 2000) 
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(Hacein-Bey-Abina et al., 2010) (Gaspar et al., 2011a) (Aiuti et al., 2002) (Aiuti et al., 2009) 
(Gaspar et al., 2011b) (Candotti et al., 2012). 
The SCID-X1 trials were associated with clinical events caused by vector genotoxicity and 
shall be discussed first. 
 
 Genotoxicity in SCID-X1 trials 
Five of the 20 patients (four in the Paris trial and one in the London trial) developed T cell 
leukemia 2 to 5.5 years after gene therapy (Hacein-Bey-Abina et al., 2008) (Howe et al., 2008). 
Interestingly enough no events occurred subsequently, suggesting reduced risk overtime. 
Following chemotherapy, four patients survived and showed sustained remission and T cell 
immunity (Hacein-Bey-Abina et al., 2010) (Gaspar et al., 2011a) (see below). One patient died 
from refractory leukemia (Hacein-Bey-Abina et al., 2010). In all cases, it was found that the 
abnormal clone had one or two provirus integrations within a proto-oncogene locus. Many other 
genomic abnormalities were found (Hacein-Bey-Abina et al., 2008; Howe et al., 2008). 
Accordingly, the clinical trials were discontinued. Considerable effort was then devoted to 
investigating the mechanism underlying these SAEs. It was clearly shown that retroviruses do 
preferentially integrate within genes (especially actively transcribed ones). Epigenetic signatures 
which favor retroviral integration have been recently identified (Dave et al., 2009; Santoni et al., 
2010). It turned out that the LMO2 locus in hematopoietic progenitors contains several of the 
features that favor frequent local integration. In parallel, it became clear that the viral LTRs' 
enhancer activity could permanently turn on transcription of the target gene and thus trigger the 
leukemic process (Santoni et al., 2010) (Cattoglio et al., 2010; Kustikova et al., 2010). It is 
noteworthy that despite the use of a similar gene transfer technology in the ADA trials, none of 
the successfully treated patients (n=28) developed leukemia - a result that significantly differs 
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from that of the SCID-X1 trials (Aiuti et al., 2009) (Gaspar et al., 2011a) (Candotti et al., 2012) 
(Ferrua et al., 2010). These findings strongly suggest that one or more disease-associated factors 
interfere with retroviral integration, e.g. the nature of progenitor cells in the bone marrow above 
the differentiation block, the possibly convergent effects of transgene and oncogene expression 
and an inadequate in vivo milieu for cell growth why gene therapy of ADA deficiency has not led 
to leukemia could be related to the toxic effects of (deoxy) adenosine metabolites, that 
accumulate because of the ADA deficiency. These effects may partially affect the epithelial 
component of the thymus. A putative diminution in  cell division rate could reduce the risk of 
secondary genomic alterations that are required to induce leukemia.The fact that a similar, 
LMO2-associated leukemic event was also observed in 4/9 WAS patient efficiently treated with 
ex vivo retrovirally mediated gene transfer into CD34 cells also indicates that the ADA deficiency 
setting should be regarded as unfavorable for the occurrence of leukemia (Boztug et al., 2010). 
Researchers have made huge efforts to construct safer vectors, with the development of 
enhancer-deleted LTR-SIN vectors containing an internal promoter. This type of vector has been 
shown to be less genotoxic in in vitro assays of the clonogenicity of myeloid precursors (Yu et 
al., 1986; Cattoglio et al., 2010; Kustikova et al., 2010). Despite efforts to set up predictive in 
vivo assays in murine models, an absolute demonstration of safety can only be provided by the 
ongoing, recently initiated clinical trials. Furthermore, use of insulators (for functional isolation 
of the integrated provirus from the genomic environment) and addition of a suicide gene might be 
useful. Nevertheless, these measures will probably be only partially effective and have their own 
pitfalls. The use of HIV-derived lentiviral vectors might constitute an additional safeguard, since 
this type of vector only integrates into genes (and not upstream of the transcription start site). 
This advantage might, however, be counterbalanced by greater transduction efficacy and thus 
more frequent vector integration into the patient's cells. Other potential improvements for the 
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future include gene targeting to neutral (“safe harbor”) genome regions and gene repair by target-
specific nucleases (Lombardo et al., 2007; Papapetrou et al., 2011). 
 
 Efficacy in the SCID-X1 trial 
At present, 18 of 20 SCID-X1 patients treated in the Paris/London trials are alive 5.7 to 13.5 
years after treatment (median: 10.3 years). Seventeen patients show the sustained presence of 
transduced lymphocytes (Cavazzana-Calvo et al., 2000) (Hacein-Bey-Abina et al., 2010) (Gaspar 
et al., 2011a). Blood T cells counts are in the normal or close-to-normal range, while phenotype 
and functional characteristics are also satisfactory. This includes detection of distinct T cell 
subsets including innate like T cells ( T cells, NK T cells) and FoxP3 (+) CD4 (+) regulatory T 
cells. Antigen-specific T cell activation can be evidenced in vitro following in vivo immunization. 
Immunoscope analysis detects a fully diversified TCRVB repertoire including in patients who 
had leukemia and received chemotherapy. Remarkably, most patients (including the 4 who 
received chemotherapy) have some naïve T cells characterized by the detection of T cell 
receptors excision circles (TREC) - indicating the presence of ongoing, long-term thymopoiesis 
from transduced progenitor cells. 
 Gene therapy based on the development of T cell immunity provided clear-cut clinical 
benefits to these patients, since they can now deal normally with infections and are doing well in 
the absence of any therapy (apart from immunoglobulin (Ig) substitution in 8 cases, see below). 
Long-term natural killer (NK) cell reconstitution is not as impressive, with only a few such cells 
in their blood (as is also observed after allogeneic HSCT in the absence of myeloablative 
conditioning). These results suggest that NK cell dynamics (precursor expansion and/or progeny 
life span) differ significantly from T cell dynamics. The patients' B cell functions have been 
8 
 
partially restored, despite very low (and decreasing) transduced B lymphocyte counts. 
Accordingly, 10 out of 18 of the patients do not require Ig substitution. This observation may be 
due to (i) to competition with normal B cell development in the absence of c expansion/function 
and (ii) B cell dynamics. It may well be of value to establish whether plasma cells in the bone 
marrow express c or not. Thanks to the development of novel methods and technologies (e.g. 
ligation-mediated PCR with multiple restriction enzymes and deep sequencing), a wealth of 
information has been provided by the in-depth analysis of retroviral integration sites in the 
patients’ cell populations. For example, it has been shown that the patients' T cells originate from 
as few as 300 to 4000 transduced progenitor cells. Given that the T cells display significant 
diversity in a TCR repertoire analysis, one can deduce that these few cells have divided 
extensively (thanks to c receptor expression) prior to TCR rearrangements in the thymus. This 
finding validates the selective advantage concept on which gene therapy for SCID was launched 
(Cavazzana-Calvo et al., 2000) (Hacein-Bey-Abina et al., 2010) (Gaspar et al., 2011a). It has also 
been noted that there is considerable variation over time in the abundance of clones, with no 
evidence for long-term selection. Furthermore, there are significant changes over time in the 
clonal composition of peripheral T cells; this could (as least in part) be explained by non-
exhaustive detection of the more rarely represented clones at a certain time point and/or by 
unexpected variations in the immune system's “use” of T cell progenitors. Lastly, although 
detection of the same integration sites in T cells and myeloid cells soon after treatment 
demonstrated that a least some multipotent hematopoietic progenitors had been transduced, only 
transduced T cells (including naïve T cells) are found 8-13 years post-gene therapy. The latter 
result suggests that T cell precursors with self renewal capacity persist in the thymus as recently 
described in murine models (Martins et al., 2012; Peaudecerf et al., 2012). 
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In addition to these 20 patients treated soon after diagnosis of a typical SCID-X1 early in life, 
five other patients were treated later in life (at between 10 and 20 years of age) because of either 
an atypical SCID-X1 caused by hypomorphic mutation or poorly reconstituted T cell immunity 
years after HSCT. Despite technically efficient gene transfer, the results have been disappointing 
- with little or no improvement in T cell immunity (Thrasher et al., 2005). Defective residual 
thymic function at a later age in SCID patients very probably accounts for these failures and 
raises the question of how long the thymus remains potentially functional in a patient lacking 
effective thymopoiesis. 
Based on the efficacy of these trials, a new clinical trial has been reinitiated for which a SIN 
retroviral vector with a satisfactory in vitro safety data (Modlich et al., 2009) containing the c 
gene has been designed. This international trial has been initiated two years ago and should 
provide within the next couple of years the expected informations on its combined safety/efficacy 
profile (Cavazzana-Calvo et al., 2012). 
 
 Gene therapy in ADA deficiency 
Adenosine deaminase deficiency has now been treated with modern gene therapy techniques, 
following the inclusion of 38 patients in three trials (performed in Italy, the UK and the USA)  
(Aiuti et al., 2002) (Aiuti et al., 2009; Ferrua et al., 2010) (Cavazzana-Calvo et al., 2012). The 
technology is essentially similar to that used to treat SCID-X1. An important difference related to 
the use of a mild conditioning regimen (4 mg/kg busulfan for most patients), in order to improve 
transduced stem cell engraftment. This choice was motivated by the fact that ADA deficiency is a 
metabolic disease in which increasing the number of transduced cells within the different cell 
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lineages could be advantageous. This chemotherapy has been well tolerated and (as mentioned 
above) none of the patients has developed treatment-related genotoxic complications. 
Efficacy (judged in terms of T cell development and the absence of clinical indications for 
supplementing patients with pegylated ADA) has been seen in 28 of the 30 patients, whereas the 
10 others are alive and on enzyme replacement therapy. The median follow-up is 3.5 years 
(range: 1 to 11.5 years). The quality of T cell reconstitution has not been as good as in SCID-X1 
(Aiuti et al., 2009) - probably because of the unfavorable setting of ADA deficiency in non-
hematopoietic tissues such as thymic epithelial cells. Nevertheless, T cell reconstitution has been 
good enough to enable the patients to thrive. The provirus integration profile and characteristics 
are strikingly similar to those seen in the SCID-X1 trial. Furthermore, significant transduced B, 
NK lymphocyte and myeloid cell counts have been detected as a consequence of the mild 
myeloablation and the transduced stem cells' good engraftment. These results are very 
encouraging and suggest that gene therapy is a coherent therapeutic option for patients with ADA 
deficiency.  
 
Gene therapy in Wiskott-Aldrich syndrome. 
Wiskott-Aldrich syndrome is a life-threatening immunodeficiency. Since lymphocyte 
development is not perturbed, transduced cells are not expected to have the full selective 
advantage observed in SCIDs. Nevertheless, this might still be partially the case, given the WAS 
protein's functional involvement in migration of CD34 cells to the bone marrow. Myeloablation 
may favor the engraftment of transduced cells. 
Lentiviral-mediated transfer of the WASp gene has now been recently initiated, in order to 
achieve optimal transduction of stem cells. This was observed in the adrenoleukodystrophy 
(ALD) trial (Cartier et al., 2009), in which up to 10% of all hematopoietic lineages were found to 
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be stably transduced 3 years after therapy. In the meantime, a retrovirus-based trial for WAS was 
set up. It is also based on ex vivo gene transfer into CD34+ cells following myeloablation. The 
recently published preliminary results suggest that many aspects of the disease (e.g. T + B cell 
immunodeficiencies and thrombocytopenia) had been corrected in 9 patients (Boztug et al., 
2010). Although longer follow-up is obviously needed, these results are sufficiently encouraging 
to justify the development of clinical trials with safer vectors (i.e SIN-LV) given the occurrence 
of leukemia in 4 into treated patients in this trial. SIN-LV vectors with a WASP promoter are 
being used in present clinical trials (Merten et al., 2011). 
 
Extending our present experience 
The results achieved to date have provided proof of concept for gene therapy of SCIDs and 
WAS. It will be critical to see whether the SIN vectors are indeed as safe as expected in the 
ongoing SCID-X1 and WAS trials. Even from a cautious standpoint, extension of gene therapy to 
other SCID diseases is logical. Encouraging preclinical results have been reported for Artemis 
and Rag-2 deficiencies and, to a lesser extent, Rag-1 deficiency (Benjelloun et al., 2008) 
(Mostoslavsky et al., 2006) (Lagresle-Peyrou et al., 2006). Further development in the treatment 
of other primary T cell immunodeficiencies (such as HLH, immunodysregulation, 
polyendocrinopathy, enteropathy and X-linked syndrome) is underway. Two strategies can be 
considered in such cases: the transduction of hematopoietic stem cells (HSCs) or that of diseased, 
mature T cells (Fischer et al., 2010). 
The fact that the sustained detection of transduced blood cells has been observed in the 
treatment of one disease (ALD) in which expression of the therapeutic transgene does not provide 
a competitive advantage suggests that a similar gene therapy strategy can be applied to PIDs 
characterized by the similar absence of growth/survival activity for the defective protein. This 
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might open up the way to the safe, efficient treatment of PIDs of the myeloid lineages, in which 
consistent transduction of HSCs will be needed to ensure the daily renewal of neutrophils. 
Chronic granulomatous diseases and leukocyte adhesion deficiency are obvious target diseases 
(Grez et al., 2011; Hunter et al., 2011).  
Advances in gene therapy for PIDs will undoubtedly stem from technological progress, such 
as the above-mentioned safe harbor and gene repair strategies. Furthermore, ex vivo stem cell 
expansion (Boitano et al., 2010) could increase the number of treated cells and hence boost 
efficacy and (if clone selection can be performed) safety. Lastly, the production of HSCs from 
other cell sources (as recently achieved with human fibroblasts(Szabo et al., 2010)) opens up 
further development pathways, together with potential gene mutation correction by genetic 
engineering based on TALE nucleases (Zhang et al., 2011) (Hockemeyer et al., 2011). 
Reprogramming of cells as achieved by the generation of induced pluripotent stem cells (iPS) 
provides a tool to engineer repair of correction of a given inherited disorder prior to induce cell 
differentiation to hematopoietic cells. Potential safety issues that might emerge from incomplete 
reprogramming as well as robustness of induced hematopoietic cells are the challenges to tackle 
next. 
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